Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Gliksman

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Oncotarget|August 22, 2015
Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicineMohamed R Akl, Poonam Nagpal, Nehad M Ayoub, et al.
Oncotarget|March 24, 2016
Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapiesMohamed R Akl, Poonam Nagpal, Nehad M Ayoub, et al.
Cancer Control : Journal of the Moffitt Cancer Center|June 5, 2020
Electrocardiographic Changes Associated With Ibrutinib ExposureMichael G Fradley, Allan Welter-Frost, Matthew Gliksman, et al.
The American Journal of Cardiology|June 19, 2019
Rates and Risk of Atrial Arrhythmias in Patients Treated With Ibrutinib Compared With Cytotoxic ChemotherapyMichael G Fradley, Matthew Gliksman, Josephine Emole, et al.
Heart (British Cardiac Society)|July 2, 2021
Association between ibrutinib treatment and hypertensionDae Hyun Lee, Fahad Hawk, Kieun Seok, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Oncotarget|August 22, 2015
Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicineMohamed R Akl, Poonam Nagpal, Nehad M Ayoub, et al.
Oncotarget|March 24, 2016
Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapiesMohamed R Akl, Poonam Nagpal, Nehad M Ayoub, et al.
Cancer Control : Journal of the Moffitt Cancer Center|June 5, 2020
Electrocardiographic Changes Associated With Ibrutinib ExposureMichael G Fradley, Allan Welter-Frost, Matthew Gliksman, et al.
The American Journal of Cardiology|June 19, 2019
Rates and Risk of Atrial Arrhythmias in Patients Treated With Ibrutinib Compared With Cytotoxic ChemotherapyMichael G Fradley, Matthew Gliksman, Josephine Emole, et al.
Heart (British Cardiac Society)|July 2, 2021
Association between ibrutinib treatment and hypertensionDae Hyun Lee, Fahad Hawk, Kieun Seok, et al.
Pageof 1